Vitamin K2 research notes

Research references and caution notes on MK-4, MK-7, arterial calcification, and related bone-health questions.

Vitamin K2 research includes dosing context and caution points. Use these sources for reference, not as a treatment protocol.

MK‑4 and fracture risk

Vitamin K2 in the MK‑4 form helps “activate” a bone protein called osteocalcin.

When osteocalcin is well activated, it can lock calcium into the bone structure more effectively, which is one reason researchers think it may help reduce fracture risk.

Several studies have tested different daily doses of MK‑4 in women with fragile bones:

In one study, a low dose (5 mg per day) worked just as well as a very high dose (45 mg per day) for activating osteocalcin in women who had already had hip or spinal compression fractures.
In another study, an even lower dose (1.5 mg per day) also improved this osteocalcin activation in postmenopausal Japanese women.
Several Japanese studies studied higher 45 mg/day doses in osteoporosis and showed improvements.

Why does this matter?

People with more “inactive” osteocalcin in their blood (under‑carboxylated osteocalcin) tend to have weaker bones and higher fracture risk in several research groups.
These trials suggest that you don’t necessarily need very high MK‑4 doses to improve this marker; smaller daily amounts may also be enough for some people.

Fraud issues in older high-dose MK-4 fracture literature

Some older high-dose fracture literature was later undermined by fraudulent data.

Several older fracture claims trace back to retracted or unreliable datasets.

However, much of the data are still valid and defensible.

What remains from validated MK-4 work?

Not every positive MK-4 study was invalid.

Some validated studies still support the 15 mg three-times-daily approach.

A more recent study suggests lower daily dosing may also be enough for osteocalcin effects.

MK-4 has a short half-life, often described as 2–3 hours.

That is why some clinicians prefer divided dosing.

The lower-dose studies above still used once-daily dosing.

That means divided dosing remains a nuance, not settled dogma.

MK-7 and bone density - mixed findings

Improved osteocalcin carboxylation does not always translate into better bone-density outcomes.

In one osteopenia trial, 375 mcg MK-7 daily improved osteocalcin carboxylation.

It did not improve bone-turnover markers, bone mineral density, or bone microarchitecture over 3 years.

In the RenaKvit dialysis trial, MK-7 was linked to faster BMD loss at the distal radius over 2 years.

The same trial also suggested prevention of lumbar spine BMD decline.

Those findings are site-specific and population-specific.

They do not automatically translate into fracture outcomes.

MK-7 and vascular stiffness ("calcification")

There is also vascular-stiffness research in postmenopausal women.

That is part of the wider arterial-calcification discussion around K vitamins.

One conference abstract reported MK-7 reduced arterial stiffness in postmenopausal women.

Women with higher baseline arterial stiffness appeared to benefit most based on blood-pressure measures.

Further work is still needed to clarify the mechanism and clinical significance.

In older men with substantial aortic-valve calcification, 720 mcg MK-7 plus 25 mcg vitamin D for 2 years did not change AVC progression.

That was a specific male population so should not be treated as a direct proxy for postmenopausal women.

K1 and MK‑4 for arterial calcification

Vitamin K1 (the main food form of vitamin K) can be converted into vitamin K2 MK‑4 inside the body.

Because of this, researchers are interested in whether low vitamin K intake or drug‑induced vitamin K depletion might make it easier for calcium to build up in blood vessels (vascular calcification).

So far, human studies using MK‑4 to reverse existing arterial calcification are very limited, and we don’t yet have strong proof that MK‑4 can undo calcium deposits in human arteries.

One important animal study looked at rats given warfarin, a blood thinner that blocks vitamin K and can promote artery calcification.

In that rat model, very high doses of vitamin K1 or MK‑4 were able to reverse warfarin-induced arterial calcification.

Animal studies suggest high-dose vitamin K can reverse warfarin-related arterial calcification. Human evidence remains limited.

References

What’s in this hub

Bone density testing: DXA interpretation, T-scores, trabecular bone score, and scan-reading pitfalls.
Lab tests and root-cause workup: Baseline bloodwork, bone-turnover markers, and specialist follow-up tests.
Diet and protein: Protein targets, mineral priorities, and oxalate-related food notes.
Supplementation: Calcium, vitamin D, magnesium, K vitamins, creatine, and related support notes.
Exercise and bone loading: Resistance work, impact loading, and bone-metastasis safety cautions.
Vitamin K2 research notes: Reference links and caution notes on MK-4, MK-7, and arterial-calcification context.
Genistein and bone health: Research notes on genistein for bone support, including oncology cautions.